ClinicalTrials.gg
WithdrawnNCT05641298REPRIEVEUpdated Jul 19, 2023

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

A Phase 2 interventional study of Sodium Fusidate and Placebo in Cystic Fibrosis and Cystic Fibrosis Pulmonary Exacerbation, sponsored by Aceragen. Withdrawn at 25 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Aceragen · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Corporate finances

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
506th of 517
0 · median 36
Started
2023
with 25 others
Phase 2
103 of 717
10 open now
Registered
627th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 506th largest by enrollment of the 517 interventional ones that give a count, is one of 26 that started in 2023, is one of 103 in phase 2, and was the 627th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 86 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic Fibrosis-related pulmonary exacerbations (PEx).

Read the detailed description

This is a Phase 2, randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of an oral ARV-1801/ACG-701 plus OBT compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with CF-related PEx.

Participants who provide informed consent (plus informed assent, if applicable) and meet all study eligibility criteria will be enrolled in the study and randomized via an interactive response technology (IRT) in a 1:1 ratio to receive ARV-1801/ACG-701 or placebo in addition to OBT for 14 days. A participant may be hospitalized (inpatient) or treated as an outpatient. If admitted to the hospital for initial treatment, the participant may be discharged at the Investigator's discretion to complete study therapy as an outpatient. The target study population will comprise 80 participants.

The duration of participation in the study for an individual participant will be approximately 28 days and will involve up to 5 clinic visits as well as the requirement to complete an electronic symptom questionnaire every day for the duration of the study. Participation will include a Screening period of up to 24 hours prior to the first dose of study drug (Day 1), a 14 day treatment course of study drug, a Day 7 visit (±1 day), an end of treatment (EOT) visit (day of last dose of study drug +3 days), and end of study (EOS) visit on Day 28 (+3 days).

03

Conditions studied

  • Cystic Fibrosis
  • Cystic Fibrosis Pulmonary Exacerbation

Browse trials for

Keywords

  • Pulmonary Exacerbation
  • Antibiotic
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females of 12 years of age and older
  2. Participants must have a confirmed diagnosis of Cystic Fibrosis with a diagnosis of an acute pulmonary exacerbation as defined as:

    1. Deterioration in 3 or more of the following symptoms for at least 48 hrs (cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, or hemoptysis) And
    2. a clinician determines that a change in CF treatment is required
  3. Participants must have a CFRSD-CRISS score of >/= 35
  4. Participants must have a moderate or Severe Patient Global Impression of Severity
  5. Participants must have a negative pregnancy test and agree to use a highly effective method of during the study and 30 days after last dose
  6. Participants must agree not to smoke during any part of the clinical trial
  7. Participants must voluntarily sign the for the study

Exclusion criteria

Exclusion Criteria:

  1. Participants cannot have any changes in any antimicrobial, bronchodilator, anti-inflammatory, CFTR modulator or medications from 28 - 3 days prior to the Screening visit.
  2. Participants cannot be receiving treatment for non-tuberculosis mycobacteria and/or Aspergillus infection.
  3. History of or allergic reaction to sodium fusidate, fusidic acid (Fucidin®) or its .
  4. Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the participant or the quality of the study data.
  5. The use of an drug or device (ie, a drug or device without the FDA approved indication) within 30 days prior to the Screening visit
  6. Known severe renal impairment, as indicated by estimated (CrCl) \<30 mL/min (by Cockcroft-Gault calculation).
  7. Evidence of significant liver disease: >3×, or direct >ULN, or total bilirubin >1.5 mg/dL; known cirrhosis with decompensation (ie, Class B or C disease).
  8. Known virus (HCV) or infection and currently receiving HCV-specific antiviral therapy. HCV infection alone, and in the absence of decompensated liver disease, is not exclusionary.
  9. Neutropenia ( \<500/µL); thrombocytopenia (\<60,000 /mm3).
  10. Known (HIV) infection and currently receiving antiretroviral therapy, or current ≤200 cells/mm3 (documented within 3 months prior to enrollment); if CD4 count is unknown, participant may not enroll.
  11. Changes to or initiation of agents (ie, prednisone [≥15mg/day], cyclosporine, tumor necrosis factor alpha [TNFα] antagonist) within 30 days of study medication administration through the EOS visit.
  12. requiring ongoing cytotoxic chemotherapy or radiation therapy.
  13. Requires concomitant treatment with ( prior to randomization allowed):

    • OATP1B1 and OATP1B3 substrates (eg, HMG-CoA reductase inhibitors [statins])
    • CYP2C8 substrates, namely glitazones (eg, repaglinide)
    • inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital, nafcillin)
    • Moderate/strong CYP3A4 inhibitors (eg, azole antifungals, erythromycin, clarithromycin)
    • P-gp substrates with narrow therapeutic windows (eg, digoxin and colchicine)
  14. Prior treatment with a CYP3A4 inducer (such as lumacaftor, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital and nafcillin) within 7 days prior to enrollment.
  15. Dietary use of large amounts of grapefruit juice and/or Seville oranges or other products containing these fruits (eg, grapefruit juice or marmalade) during the study.
  16. Participant requiring warfarin therapy.
  17. Seizure disorder requiring current therapy with an anticonvulsant.
  18. Female participant who is pregnant or lactating.
  19. History of /current chronic alcohol consumption and/or drug abuse (including cannabis use).
  20. Any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    ARV-1801(ACG-701) Active Group

    ARV-1801(ACG-701) tablets by mouth twice a day for 14 days

    Drug: Sodium Fusidate

  • Placebo comparator
    Placebo Group

    Placebo tablets by mouth twice a day for 14 days

    Drug: Placebo

Interventions

  • Tablets

    Also known as: ACG-701, ARV-1801

  • DrugPlacebo

    Tablets

06

What researchers measure

Primary outcomes

  1. Desirability in outcome ranking (DOOR)

    To demonstrate that the addition of oral ARV-1801(ACG-701) to OBT is superior to placebo plus OBT based on DOOR in cystic fibrosis pulmonary exacerbations.

    Time frame: Day 7

07

Study locations

25 sites
  • University of Florida
    Gainesville, Florida 32610, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • Nemours Children's Health - Pensacola
    Pensacola, Florida 32514, United States
  • Johns Hopkins All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Cystic Fibrosis Center of Chicago
    Chicago, Illinois 60093, United States
  • Cystic Fibrosis Center of Chicago
    Northfield, Illinois 60093, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan, Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63114, United States
  • UNMC-Nebraska CF Pediatric Center
    Omaha, Nebraska 68114, United States
  • Gunnar H. Esiason Adult Cystic Fibrosis Center
    Morristown, New Jersey 07960, United States
  • New York Medical College
    Hawthorne, New York 10532, United States
  • University of Rochester Medical Center Strong Memorial
    Rochester, New York 14642, United States
  • Rainbow Babies and Children's Hospital/Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Cook Children's Health Care System
    Fort Worth, Texas 76104, United States
  • The University of Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Sep 2023, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 7, 2022
StartActual
Feb 10, 2023
Primary completionEst.
Sep 2023
CompletionEst.
Sep 2023
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05641298
Lead sponsor
Aceragen
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Feb 10, 2023
Primary completion
Sep 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Jul 19, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fusidic Acid

Start the discussion